ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 708,72
-0,02%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Abeona Therapeutics Inc (ABEO)

  7. Abeona Therapeutics Inc (ABEO) Actualités

ABEO

Abeona Therapeutics (ABEO)

Abeona Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ABEO
DateHeureSourceTitreSymboleSociété
28/05/202413h30GlobeNewswire Inc.Abeona Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:ABEOAbeona Therapeutics Inc
20/05/202414h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABEOAbeona Therapeutics Inc
15/05/202422h31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ABEOAbeona Therapeutics Inc
15/05/202413h35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABEOAbeona Therapeutics Inc
15/05/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABEOAbeona Therapeutics Inc
15/05/202413h30GlobeNewswire Inc.Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate ProgressNASDAQ:ABEOAbeona Therapeutics Inc
13/05/202423h03Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ABEOAbeona Therapeutics Inc
07/05/202413h30GlobeNewswire Inc.Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ABEOAbeona Therapeutics Inc
03/05/202413h30GlobeNewswire Inc.Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:ABEOAbeona Therapeutics Inc
22/04/202422h05GlobeNewswire Inc.Abeona Therapeutics Provides Regulatory Update on Pz-celNASDAQ:ABEOAbeona Therapeutics Inc
18/03/202412h30GlobeNewswire Inc.Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA InspectionsNASDAQ:ABEOAbeona Therapeutics Inc
14/02/202422h51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABEOAbeona Therapeutics Inc
01/02/202413h30GlobeNewswire Inc.Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)NASDAQ:ABEOAbeona Therapeutics Inc
08/01/202413h30GlobeNewswire Inc.Abeona Therapeutics Announces $50 Million Credit FacilityNASDAQ:ABEOAbeona Therapeutics Inc
27/11/202313h30GlobeNewswire Inc.Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)NASDAQ:ABEOAbeona Therapeutics Inc
13/11/202313h30GlobeNewswire Inc.Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate DevelopmentsNASDAQ:ABEOAbeona Therapeutics Inc
26/09/202313h30GlobeNewswire Inc.Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis BullosaNASDAQ:ABEOAbeona Therapeutics Inc
12/09/202313h30GlobeNewswire Inc.Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial OfficerNASDAQ:ABEOAbeona Therapeutics Inc
07/09/202313h30GlobeNewswire Inc.Abeona Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:ABEOAbeona Therapeutics Inc
30/08/202313h30GlobeNewswire Inc.Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA SubmissionNASDAQ:ABEOAbeona Therapeutics Inc
08/08/202313h30GlobeNewswire Inc.Abeona Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:ABEOAbeona Therapeutics Inc
28/07/202313h30GlobeNewswire Inc.Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023NASDAQ:ABEOAbeona Therapeutics Inc
19/07/202314h30GlobeNewswire Inc.Abeona Therapeutics Joins Rare Disease Company CoalitionNASDAQ:ABEOAbeona Therapeutics Inc
10/07/202316h41Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABEOAbeona Therapeutics Inc
07/07/202314h30GlobeNewswire Inc.Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ABEOAbeona Therapeutics Inc
03/07/202314h45GlobeNewswire Inc.Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ABEOAbeona Therapeutics Inc
03/07/202314h34Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ABEOAbeona Therapeutics Inc
16/06/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ABEOAbeona Therapeutics Inc
09/06/202313h30GlobeNewswire Inc.Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101NASDAQ:ABEOAbeona Therapeutics Inc
01/06/202313h30GlobeNewswire Inc.Abeona Therapeutics to Present at the Jefferies Healthcare ConferenceNASDAQ:ABEOAbeona Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ABEO

Dernières Valeurs Consultées

FTSE
UKX
FTSE 100
NYSE
JPM
JP Morgan Chase
NASDAQ
MSFT
Microsoft
NYSE
DIS
Walt Disney
EU
VK
Vallourec
EU
BNP
BNP Paribas
COIN
BTCUSD
Bitcoin
NASDAQ
GOOGL
Alphabet
EU
BN
Danone
NASDAQ
NVDA
NVIDIA
NYSE
MCD
McDonalds
EU
GLE
Societe Generale
EU
RI
Pernod Ricard
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés